FibroGen, Inc. Expected to Earn Q1 2025 Earnings of $0.00 Per Share (NASDAQ:FGEN)

FibroGen, Inc. (NASDAQ:FGEN - Free Report) - Analysts at William Blair decreased their Q1 2025 earnings per share (EPS) estimates for shares of FibroGen in a report issued on Tuesday, May 7th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their previous estimate of $0.04. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for FibroGen's current full-year earnings is ($1.09) per share.

FibroGen Price Performance

NASDAQ:FGEN traded up $0.09 during trading hours on Thursday, hitting $1.22. The company's stock had a trading volume of 2,621,023 shares, compared to its average volume of 2,712,639. The stock has a fifty day simple moving average of $1.67 and a 200-day simple moving average of $1.24. The company has a market capitalization of $121.36 million, a P/E ratio of -0.50 and a beta of 0.88. FibroGen has a twelve month low of $0.33 and a twelve month high of $19.47.

FibroGen (NASDAQ:FGEN - Get Free Report) last released its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.15). The company had revenue of $27.14 million during the quarter, compared to analyst estimates of $40.00 million.

Hedge Funds Weigh In On FibroGen

Several large investors have recently bought and sold shares of FGEN. Armistice Capital LLC raised its position in FibroGen by 81.2% in the third quarter. Armistice Capital LLC now owns 7,892,000 shares of the biopharmaceutical company's stock valued at $6,810,000 after purchasing an additional 3,536,000 shares during the last quarter. Acadian Asset Management LLC bought a new position in FibroGen in the third quarter valued at about $1,391,000. Primecap Management Co. CA raised its position in FibroGen by 7.7% in the third quarter. Primecap Management Co. CA now owns 14,724,968 shares of the biopharmaceutical company's stock valued at $12,706,000 after purchasing an additional 1,047,380 shares during the last quarter. Pennant Investors LP bought a new position in FibroGen in the fourth quarter valued at about $681,000. Finally, Assenagon Asset Management S.A. raised its position in FibroGen by 49.7% in the third quarter. Assenagon Asset Management S.A. now owns 2,226,857 shares of the biopharmaceutical company's stock valued at $1,922,000 after purchasing an additional 739,166 shares during the last quarter. 72.71% of the stock is currently owned by institutional investors.

Insider Activity at FibroGen

In other FibroGen news, CEO Thane Wettig acquired 50,000 shares of FibroGen stock in a transaction that occurred on Thursday, March 7th. The shares were acquired at an average cost of $1.91 per share, with a total value of $95,500.00. Following the completion of the purchase, the chief executive officer now directly owns 470,178 shares of the company's stock, valued at approximately $898,039.98. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.98% of the stock is currently owned by insiders.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.